Improving Outcomes in Gynecologic Cancers
Meeting Series
Meeting Series

Improving Outcomes in Gynecologic Cancers

PARP Inhibition and Immunotherapeutic Approaches

Not a member of My prIME? Join now for instant access.

Don’t miss this meeting in your area! Hear from the experts about current and emerging therapies for gynecologic malignancies. Topics will include PARP inhibition and immunotherapeutic approaches for ovarian, cervical, and endometrial cancers. Attendees will have the opportunity to interact with expert faculty throughout the meeting.



1.0 AMA PRA Category 1 Credit™

This live meeting series is designed to cover the latest current and emerging therapies for gynecologic malignancies. Topics include PARP inhibition and immunotherapeutic approaches, as well as combination strategies, for ovarian, cervical, and endometrial cancers. Take this opportunity to engage with an expert on PARP and immunotherapy in gynecologic oncology throughout the meeting.

This activity is intended for gynecologic oncologists, medical oncologists, oncology nurses, and other members of the cancer care team involved in the management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Incorporate PARP inhibitors into treatment regimens for patients with ovarian cancer
  • Devise effective strategies for treating patients with ovarian and cervical cancer with checkpoint inhibitors and PARP inhibitors, both alone or in combination
  • Describe safety and efficacy data of PARP inhibition and immunotherapy in endometrial cancer

Nursing learning objectives:

  • Identify FDA-approved therapies for patients with ovarian cancer
  • Develop communication tools for relaying the efficacy and safety of approved treatments for gynecologic cancers to patients

This educational activity is supported by grants from AstraZeneca; Clovis Oncology; Merck and Co., Inc.; and TESARO, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

The criteria for successful completion include attending the full program and completing the evaluation.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact us prior to the live event using our contact form.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.